Please assess the completion status of the following clinical trial:

Trial Title: A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria for AD population:~* Diagnosis of Atopic Dermatitis (AD) for at least 3 months~* Investigator's Global Assessment (IGA) score of 2 (mild), or 3 (moderate)~* AD covering 5% and up to 40% of Body Surface Area (BSA)~* A Peak Pruritus Numerical Rating Scale (PP-NRS) average score of ≥2~Inclusion Criteria for Plaque Psoriasis~* Diagnosis of Plaque Psoriasis (PsO) for at least 6 months~* Physician Global Assessment (PGA) score of 2 (mild), 3 (moderate), or 4 (severe)~* PsO covering 2% to 20% (inclusive) of BSA~Exclusion Criteria:~* Presence of skin comorbidities that would interfere with study assessment or response to treatment~* Psychiatric condition including recent or active suicidal ideation or behavior~* Current or recent history of severe, progressive, or uncontrolled disease~* A history of systemic, chronic or acute skin infection requiring hospitalization, parenteral antimicrobial therapy, or is judged clinically significant.~* Recent, significant trauma or major surgery~* History of cancer or have undergone treatment for any type of cancer, with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ with no evidence of recurrence.~* History of angioedema or anaphylaxis to topical products or known sensitivity to any of the components of the investigational products.~* Use of any prohibited concomitant medication(s)~* Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).~* Participants with an estimated glomerular filtration rate (eGFR) of \<40 mL/min/1.73m2 calculated using the serum creatinine-based Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula for adults and serum creatinine \>1.5 x upper limit of normal (ULN) in adolescents (12-18 years old)~* Participants with total bilirubin ≥2x ULN (≥3 x ULN for Gilbert's disease), aspartate aminotransferase (AST) ≥2.5 x ULN, ALT ≥2.5 x ULN.~* Clinically relevant abnormal baseline standard 12-lead electrocardiogram (ECG) including, but not limited to QTC corrected using Fridericia's Formula (QTcF) interval \>450 msec and QRS \> 120 msec~* A recent history of alcohol or substance abuse

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atopic Dermatitis PF-07038124 0.01% ointment (Type: EXPERIMENTAL): Atopic Dermatitis
- Atopic Dermatitis Vehicle ointment (Type: PLACEBO_COMPARATOR): Atopic Dermatitis
- Atopic Dermatitis PF-07038124 0.03% ointment (Type: EXPERIMENTAL): Atopic Dermatitis
- Plaque Psoriasis PF-07038124 0.01% ointment (Type: EXPERIMENTAL): Plaque Psoriasis
- Plaque Psoriasis PF-07038124 0.03% ointment (Type: EXPERIMENTAL): Plaque Psoriasis
- Plaque Psoriasis PF-07038124 0.06% ointment (Type: EXPERIMENTAL): Plaque Psoriasis
- Plaque Psoriasis Vehicle ointment (Type: PLACEBO_COMPARATOR): Plaque Psoriasis

Based on this trial design, predict the completion outcome and termination type (if applicable).